|
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute …
Sacramento Bee One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling … Rigel moving asthma drug into mid-stage trial |
View full post on asthma – Google News